A Single and Multiple Ascending Dose study of AB-423 in in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 14 Mar 2018
At a glance
- Drugs AB 423 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; First in man
- 14 Mar 2018 Status changed from recruiting to completed,According to an Arbutus Biopharma Corporation media release.
- 02 Nov 2017 According to an Arbutus Biopharma Corporation media release, results from this trial are expected in mid-2018.
- 24 Oct 2017 Interim results (n=32) presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases